New oral disease-modifying therapies for multiple sclerosis
Open Access
- 8 May 2009
- journal article
- Published by H1 Connect in F1000 Medicine Reports
- Vol. 1 (34)
- https://doi.org/10.3410/m1-34
Abstract
New oral disease-modifying therapies for multiple sclerosisThis publication has 29 references indexed in Scilit:
- Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosisNeurology, 2008
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosisNeurology, 2008
- Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple SclerosisPLOS ONE, 2008
- Emerging oral therapies for multiple sclerosisInternational Journal of Clinical Practice, 2007
- Combination of IFNβ‐1a (Avonex®) and mycophenolate mofetil (Cellcept®) in multiple sclerosisEuropean Journal of Neurology, 2007
- Serum 25-Hydroxyvitamin D Levels and Risk of Multiple SclerosisJAMA, 2006
- Disruption of the interaction of T cells with antigen‐presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formationArthritis & Rheumatism, 2005
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- The Cladribine Trial in Secondary Progressive Multiple Sclerosis: A ReanalysisNeuroepidemiology, 2000
- Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic useBritish Journal of Dermatology, 1999